Avgoustou Elena, Tzivaki Ilektra, Diamantopoulou Garyfalia, Zachariadou Tatiana, Avramidou Despoina, Dalopoulos Vasileios, Skourtis Alexandros
Second Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokratio General Hospital, Vasilissis Sofias 114, 11527 Athens, Greece.
First Department of Internal Medicine, Sismanogleio General Hospital, 37 Sismanogliou Str., 15126 Athens, Greece.
Diagnostics (Basel). 2025 Jan 14;15(2):169. doi: 10.3390/diagnostics15020169.
Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.
肥胖已成为一种全球性流行病,伴有影响深远的健康并发症,包括其作为慢性肾脏病(CKD)独立危险因素的作用。越来越多的证据表明,肥胖通过多种机制导致CKD,包括慢性炎症、血流动力学改变、胰岛素抵抗和脂质蓄积。这些过程最终可导致组织病理学变化,统称为肥胖相关肾小球病(ORG)。本综述旨在全面概述目前关于ORG的患病率、临床表现和病理生理学的知识。此外,我们强调识别有助于早期检测ORG的关键生物标志物的重要性。最后,我们探讨了有望缓解这一日益严重的全球健康危机的新兴治疗策略。